Navigation Links
Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
Date:3/27/2013

tudy is predicated on a prospective subgroup analysis conducted in the Phase 2b PEARL-SC study, which was reported in July 2012. In this analysis, a significant improvement in SRI-8 was observed in patients who received subcutaneous blisibimod (200mg QW) compared to those treated standard steroid therapy (N=95, 41.7% versus 10.4% respectively, p<0.001). This finding was corroborated by the separate analysis of SRI-8 responder rates conducted in the entire study population (N=547). The CHABLIS-SC1 study was reviewed by the US Food and Drug Administration as part of an "End of Phase 2" meeting in September 2012.

"The initiation of the CHABLIS-SC1 study marks a critical milestone for Anthera. The insight from our Phase 2b clinical study supports our belief that blisibimod may be a highly effective treatment option for the more severely ill lupus patients compared to currently available therapeutics," said Colin Hislop , MD, Anthera's Chief Medical Officer. "We are excited to advance blisibimod's development. Today we have taken another step towards making a much needed treatment available for this unpredictable and devastating disease."

About B-Cell Activating Factor (BAFF) and blisibimod

BAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy, lupus nephritis, rheumatoid arthritis, multiple sclerosis, Sjogren's Syndrome, Graves' Disease and others. Multiple clinical studies with other BAFF antagonists recently have reported on the potential positive role on BAFF inhibitors in treating lupus and rheumatoid arthritis with concomitant decreases in B-cells, plasma cells and autoantibodies. Anthera is advancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel protein compromised of high-affinity BAFF binding domains fused to a human Fc domain,
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
5. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
10. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
11. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  BC Technical, the largest nationwide, non-OEM ... , Inc., a leading provider of Siemens Nuclear Medicine ... agreement naming BC Technical as the authorized provider of ... MiE and BC Technical announced today that the two ... Technical as the service and systems provider for MiE,s ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
(Date:7/10/2014)... 2014   LabStyle Innovations Corp . (OTCQB:DRIO), developer ... the appointment of Professor Richard B. Stone ... of Directors. Prof. Stone brings over ... LabStyle as an entrepreneur, venture capitalist public, company ... expert. He currently serves on the board of ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... With obesity in America reaching alarming levels -- across our adult and youth ... who used BodyMedia,s wearable body-monitoring technology either in conjunction with a group weight loss ... three times more weight than individuals who attempted ... ...
... Ill., March 11 The U.S. Food ... supplemental new drug application (sNDA) of a new six-month ... Depot (leuprolide acetate for depot suspension) for ...  Palliative treatment helps to relieve symptoms associated with advanced ...
Cached Medicine Technology:The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 2The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 3The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 4The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 5The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 6Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 2Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 3Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 4Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 5Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 6Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 7
(Date:7/12/2014)... "The second toes cross over the big toes on my ... an inventor from East Hartford, Conn. This gave him idea ... He then created a prototype of the Comfort Sock, which ... toes from overlapping. This avoids discomfort and pain, which allows ... use, it's ideal for people with foot problems, athletes and ...
(Date:7/12/2014)... York, New York (PRWEB) July 12, 2014 ... continue to move forward in U.S. courts, Bernstein Liebhard ... ties elevated metal ion levels to the failure of ... July 2nd issue of The Journal of Bone & ... had received unilateral Articular Surface Replacement prostheses at least ...
(Date:7/12/2014)... NY (PRWEB) July 12, 2014 ... 2020 - New and Late-Stage Four-Factor PCCs and ... analysis of the critical care market in the ... Canada. The report provides an estimation of market ... 2020. It covers critical care indications that are ...
(Date:7/12/2014)... Arab Emirates (PRWEB) July 12, 2014 ... Los Angeles basketball legend is heading to the UAE. ... and six-time champion will be in the UAE from ... Fitness Weekend in support of diabetes awareness. The event ... award-winning entertainment marketing and event management company based in ...
(Date:7/12/2014)... Restore My Vision Today is a ... a couple boasting very impressive credentials on the field ... Today as a way to help consumers do without ... their respective patients’ treatments . , In ... trove of pertinent information relevant to eye care like:, ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3
... Omega-3 polyunsaturated fatty acids it has been revealed that ... benefits. // ,They influence mood, personality and behavior ... by University of Pittsburgh School of Medicine researchers at ... Society in Denver. ,The study comprised 106 ...
... who died on Saturday suspected to be of bird flu ... high alert.// ,The 32-year-old man is believed ... a busy city in China's Guangdong province, bordering Hong Kong. ... and died within nine days of hospitalisation. ,Many ...
... Justice Cyriac Joseph has expressed the need for quality ... must not leave any stone unturned to weed out ... Justice, this is a matter of grave concern to ... education. The educationists, professionals, governments and all the stakeholders ...
... University Medical Center researchers have discovered that distinct regions ... faced with ambiguous choices versus// choices involving only risk. ... risky choices, and how such risk-taking can become an ... were published in the journal Neuron. ,The ...
... and sound health info Kerala and Goa have lifted the ... revealed by Minister for Medical Education and Animal Husbandry V.S. ... that this indicates that the situation is under control. ... make policies Chief Minister H.D. Kumaraswamy said the Government has ...
... decided to test the effects of radiation released from of ... human skin in order to determine if these transmissions are ... is scheduled to begin sometime next week will expose a ... phone radiation for about 60 minutes or the duration of ...
Cached Medicine News:Health News:Distinct Brain Sections Are Activated While Making Risky Decisions 2
... slot into the side ... monitor, so patient information ... patient's side. Data is ... and storage at the ...
... Telemetry System is a telemetry system ... which require monitoring and performance. With ... able to monitor patients from virtually ... and wireless bedsides. Now, monitoring your ...
TeleRehab Advantage is a monitoring system that automates the generation of outcomes data. Patient information and session information is automatically transferred from the monitoring program to Outc...
... Clearly, the ISI Lexan Universal ... surgical table for lower and ... head and neck, and lower ... traction package gives you the ...
Medicine Products: